SAB Biotherapeutics, Inc. (SABSW) stock
SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS
$0.01+0.00 (+33.33%)
Close on Oct 20, 2026Market cap $304.80MP/E –Yield –
SAB Biotherapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
SAB Biotherapeutics's total debt was $0 at Dec 31, 2024. For fiscal 2024 it was $0. The highest annual figure on record is $541.64K in fiscal 2022.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | – |
| FY2023 | Dec 31, 2023 | $0 | -100.0% |
| FY2022 | Dec 31, 2022 | $541.64K | – |
| FY2021 | Dec 31, 2021 | $0 | -100.0% |
| FY2020 | Dec 31, 2020 | $172.04K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q4 FY2022 | Dec 31, 2022 | $541.64K | +214.8% |
| Q2 FY2022 | Jun 30, 2022 | $0 | – |
| Q1 FY2022 | Mar 31, 2022 | $0 | – |
| Q4 FY2021 | Dec 31, 2021 | $0 | – |
| Q4 FY2020 | Dec 31, 2020 | $172.04K | – |